Vicore Pharma Holding AB (publ) (STO:VICO)

Sweden flag Sweden · Delayed Price · Currency is SEK
8.77
-0.10 (-1.13%)
Aug 4, 2025, 9:59 AM CET
-1.13%
Market Cap2.08B
Revenue (ttm)6.00M
Net Income (ttm)-311.88M
Shares Out234.61M
EPS (ttm)-1.86
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume68,353
Average Volume287,794
Open8.87
Previous Close8.87
Day's Range8.71 - 9.01
52-Week Range6.09 - 17.61
Beta0.34
RSI59.28
Earnings DateAug 22, 2025

About Vicore Pharma Holding AB

Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary arterial hypertension. It also developing Almee, an investigational medical device in clinical development that has completed Pha... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 29
Stock Exchange Nasdaq Stockholm
Ticker Symbol VICO
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.